Oncology Polycythemia Vera: Factors That May Warrant a Change in Cytoreductive Therapy expert roundtables By Katherine Walsh, MD, FACP; Rami S. Komrokji, MD; Ruben A. Mesa, MD, FACP
Oncology Elevated Counts and Thrombotic Risk in Patients With Polycythemia Vera patient care perspectives By Rami S. Komrokji, MD
Oncology Resistance or Intolerance to Hydroxyurea in Patients With Polycythemia Vera patient care perspectives By Ruben A. Mesa, MD, FACP
Oncology Treatment Recommendations for Durable Count Control in Polycythemia Vera clinical topic updates By Ruben A. Mesa, MD, FACP
Oncology Traditional and Nontraditional Risk Factors in Patients With Myeloproliferative Neoplasms clinical topic updates By Rami S. Komrokji, MD